Visits: 3
Biogen CEO Michel Vounatsos told CNBC that the list price of $56,000 per year for the company’s FDA-approved Alzheimer’s disease drug aducanumab is “fair.” Read More Go To Source
Visits: 3
Biogen CEO Michel Vounatsos told CNBC that the list price of $56,000 per year for the company’s FDA-approved Alzheimer’s disease drug aducanumab is “fair.” Read More Go To Source
Copyright © 2020 | Fastinews.com